Based on your response, it appears that your Stage I/II/IIIa breast cancer is not estrogen receptor-positive (ER+) or is HER2 positive.
The Oncotype DX breast cancer test is a genomic test that may help guide treatment decisions for patients with non-invasive breast cancer, often referred to as ductal carcinoma in situ (DCIS), and help early-stage invasive breast cancer patients with estrogen receptor-positive (ER+) HER2 negative disease with node negative or up to three positive lymph nodes evaluate if they will benefit from chemotherapy.
For information on treatment options for estrogen receptor-negative breast cancer, please consider visiting: www.breastcancer.org.
Return to the eligibility start page.
If you have questions and would like to speak about an Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).